Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 602.11M P/E - EPS this Y -26.10% Ern Qtrly Grth -
Income -102.07M Forward P/E -3.74 EPS next Y -17.80% 50D Avg Chg 31.00%
Sales 34.48M PEG -0.20 EPS past 5Y - 200D Avg Chg 10.00%
Dividend N/A Price/Book 1.56 EPS next 5Y 14.50% 52W High Chg -46.00%
Recommedations 1.80 Quick Ratio 11.76 Shares Outstanding 90.31M 52W Low Chg 78.00%
Insider Own 12.42% ROA -18.00% Shares Float 68.48M Beta 2.59
Inst Own 80.33% ROE -30.50% Shares Shorted/Prior 10.07M/9.69M Price 7.06
Gross Margin -225.07% Profit Margin -296.05% Avg. Volume 3,073,053 Target Price 20.00
Oper. Margin -1,052.33% Earnings Date - Volume 1,542,529 Change -3.42%
About Caribou Biosciences, Inc.

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Caribou Biosciences, Inc. News
03/14/24 All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy
03/13/24 11 Oversold NASDAQ Stocks To Buy Right Now
03/12/24 Why Caribou Biosciences Stock Is Crashing Today
03/11/24 Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
03/05/24 Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
02/26/24 12 $10 Stocks That Will Triple
02/26/24 Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold
02/23/24 Steven Cohen's Point72 Adds Caribou Biosciences Inc to Its Portfolio
02/15/24 Caribou Biosciences to Participate in Upcoming Investor Conferences
02/12/24 2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
02/07/24 Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans
01/15/24 3 Biotech Stocks You Can Buy and Hold for the Next Decade
01/07/24 Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
12/13/23 3 Gene-Editing Stocks With the Potential to Mint Millionaires
12/12/23 Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
12/08/23 Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock?
12/06/23 Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade
11/20/23 Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect?
11/18/23 Subdued Growth No Barrier To Caribou Biosciences, Inc. (NASDAQ:CRBU) With Shares Advancing 28%
11/07/23 Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
CRBU Chatroom

User Image RocroBio Posted - 18 hours ago

$CRBU rounding bottom in tact still. looking for a pop

User Image RocroBio Posted - 18 hours ago

sold entire $AMAT position at 205. 112 was my avg. Swung profits into $PFE and $CRBU. Oncology is going to be massive once ai comes into the space. allogenic phase 3 trials very clearly rival autologous market standard treatment. ai this ai that, wait until it comes into medicine. That’s where the money is. Pfizer is sitting on piles of cash, my bet is they start ramping up buyouts. 30 by summer

User Image Windytimes Posted - 18 hours ago

$CRBU Q2 is officially upon us the next trading day.

User Image Jidane Posted - 18 hours ago

$CRBU Now 2Q, wish you luck. I hope data is good enough. enough than before.

User Image Sandpiper22 Posted - 22 hours ago

$CRBU seen this movie before…hard to buy now, but when it’s $10-12 a share, you’ll be kicking yourself that you didn’t buy more!

User Image biochirp Posted - 23 hours ago

$XBI $CRBU lagging

User Image OTM6 Posted - 1 day ago

$CRBU

User Image elgreg Posted - 1 day ago

$CRBU Caribou posted this statement today H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference March 26, 2024 There was a technical issue with the H.C. Wainwright webcast and this event did not take place.

User Image lonelywarrior Posted - 1 day ago

$CRBU Will run up fast once volume is back.

User Image PorkyPig Posted - 2 days ago

$CRBU I've been picking up CRBU shares since we hit the $5's again. NTLA looks like a good bargain but to me but I've been buying CRBU exclusively. It seems like the best bang for the buck right now, all you need is some patience to sit on it for a couple of years.

User Image elgreg Posted - 2 days ago

$CRBU Favorable Dosing Data! shorts will be Annihilated

User Image elgreg Posted - 2 days ago

$CRBU Bring on the the dosing data we-have no reason to believe that it won be positive. No Fear!

User Image biochirp Posted - 2 days ago

$CRBU $IPSC

User Image Windytimes Posted - 2 days ago

$CRBU we are days away from Q2 so put up or shut up time.

User Image Sandpiper22 Posted - 2 days ago

$CRBU let’s see $6 today 📈

User Image OTM6 Posted - 2 days ago

$CRBU still looking for bottom.

User Image elgreg Posted - 2 days ago

$CRBU Low volume easier to manipulate!

User Image BUFox19 Posted - 2 days ago

$CRBU why is it still dropping?

User Image steven1x Posted - 2 days ago

$CRBU http://investor.cariboubio.com/events/event-details/2024-rbc-capital-markets-global-healthcare-conference

User Image steven1x Posted - 2 days ago

$CRBU http://investor.cariboubio.com/events/event-details/bofa-securities-2024-healthcare-conference

User Image elgreg Posted - 2 days ago

$CRBU The webcast conference was canceled do technical issues H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

User Image Smith3_1 Posted - 2 days ago

$CRBU https://twitter.com/GrantedPatents/status/1772619340375785915?t=fc_oJFv5tPoN0kgNGauGUQ&s=19

User Image OverTheShoulderBagHolder Posted - 2 days ago

$CRBU data release 2 weeks from today

User Image elgreg Posted - 3 days ago

$CRBU The latest number of shares shorted for Caribou Biosciences (CRBU) is reported to be around 9.39 million This represents approximately 10.40% of outstanding shares and 13.71% of the float [various sources].

User Image Sandpiper22 Posted - 3 days ago

$CRBU bounce time 📈

User Image elgreg Posted - 3 days ago

$CRBU Bought additional shares Cheap! Cheap! Cheap! Can’t resist a good sale!

User Image Windytimes Posted - 3 days ago

$CRBU and just like that Red…

User Image Windytimes Posted - 3 days ago

$CRBU it wants but get smacked down every morning by the wall of doubt

User Image RocroBio Posted - 3 days ago

$CRBU

User Image RocroBio Posted - 3 days ago

$CRBU

Analyst Ratings
HC Wainwright & Co. Buy Mar 19, 24
RBC Capital Outperform Mar 12, 24
Cantor Fitzgerald Neutral Nov 8, 23
HC Wainwright & Co. Buy Jul 26, 23
Truist Securities Buy Jul 14, 23
Truist Securities Buy Jul 11, 23
HC Wainwright & Co. Buy May 10, 23
HC Wainwright & Co. Buy Mar 14, 23
RBC Capital Outperform Mar 10, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Haurwitz Rachel E. President and CEO President and CEO Mar 20 Option 2.96 10,000 29,600 30,000 03/22/23
Kanner Steven Chief Scientific Off.. Chief Scientific Officer Dec 02 Option 2.69 21,401 57,569 323,460 12/02/22
Kanner Steven Chief Scientific Off.. Chief Scientific Officer Aug 25 Option 2.69 43,248 116,337 345,307 08/26/22
Kanner Steven Chief Scientific Off.. Chief Scientific Officer Aug 25 Sell 11.22 43,248 485,243 302,059 08/26/22
Kanner Steven Chief Scientific Off.. Chief Scientific Officer May 13 Option 2.25 74,420 167,445 302,059 05/17/22
Haurwitz Rachel E. President and CEO President and CEO May 09 Option 2.96 10,000 29,600 20,000 05/10/22
Haurwitz Rachel E. President and CEO President and CEO Jan 26 Option 2.96 10,000 29,600 10,000 05/10/22
Fischesser Ryan VP of Finance and Co.. VP of Finance and Controller May 05 Option 3.4 2,274 7,732 115,518 05/06/22
Fischesser Ryan VP of Finance and Co.. VP of Finance and Controller Mar 15 Option 3.4 2,274 7,732 113,244 03/17/22
Kanner Steven Chief Scientific Off.. Chief Scientific Officer Mar 04 Option 3.4 10,720 36,448 227,639 03/07/22
O'Byrne Jason Chief Financial Offi.. Chief Financial Officer Feb 08 Option 4.11 24,336 100,021 24,336 02/08/22
Fischesser Ryan VP of Finance and Co.. VP of Finance and Controller Jan 11 Buy 3.4 7,387 25,116 109,082 01/12/22
MCCLUNG BARBARA G Chief Legal Officer Chief Legal Officer Oct 20 Buy 2.69 9,219 24,799 342,844 10/21/21
Kanner Steven Chief Scientific Off.. Chief Scientific Officer Oct 12 Buy 2.1 114,860 241,206 215,031 10/13/21